REJOICE-Ovarian01 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Representative image of U.S. Air Force defense data infrastructure and enterprise IT systems, illustrating how Dell Technologies’ EMC contract win could support military test data modernization.

Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy

Read More

Pharma Industry News

Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial

Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.

bySoujanya Ravi

October 20, 2025

web analytics